PaySign, Inc. (PAYS) Stock

PaySign, Inc. (PAYS) is a Technology stock trading at $14.09 (as of 2026-08-21), with a market capitalization of $795.55M and a trailing P/E of 40.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

PaySign, Inc. provides prepaid card products and processing services under the PaySign brand for corporate, consumer, and government applications. It offers various services, such as transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service through PaySign, a proprietary card-processing platform. The company also develops prepaid card programs for corporate incentive and rewards, including consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, and pharmaceutical payment assistance; and payroll or general purpose reloadable cards, as well as gift or incentive cards. In addition, it offers and Per Diem/Corporate Expense Payments that allows businesses, and non–profits and government agencies the ability to control employee spending while reducing administration costs by eliminating the need for traditional expense reports. Further, the company provides payment claims processing and other administrative services; pharmacy-based voucher and copay, and medical claims and debit-based affordability programs; PaySign Premier, a demand deposit account debit card; and payment solution for source plasma collection centers, as well as customer service center and PaySign Communications Suite services. Its principal target markets for processing services comprise prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and Mexico. The company was formerly known as 3PEA International, Inc. and changed its name to PaySign, Inc. in April 2019. PaySign, Inc. was incorporated in 1995 and is based in Henderson, Nevada.

Understand PaySign, Inc.: how it makes money

PaySign provides prepaid card products and processing services, using its proprietary card-processing platform to handle transaction processing, cardholder enrollment, value loading, and cardholder account management for corporate, consumer, and government applications.

PaySign's earnings are structurally tied to operating prepaid card programs through its proprietary platform, where revenue depends on ongoing program activity and scale across cardholders and program operators such as plasma donation centers and patient affordability programs.

Revenue by segment (latest quarter)
Plasma$0.0B
Pharma$0.0B
Other$0.0B

Business quality (Strong): Good visibility into the operating model and several scale KPIs (cardholders, centers, programs), but the provided segment breakdown is limited and some segment revenue labels are effectively 0.0B, so segment mix confidence is moderate.

Valuation: Trades at 48× trailing earnings · $0B market cap.

Bull case

  • End-to-end prepaid card program operations: PaySign runs card processing activities including transaction processing, cardholder enrollment, value loading, and cardholder account management, supported by its proprietary card-processing platform.
  • Multiple application types within prepaid and healthcare-adjacent programs: Programs include corporate incentive and rewards, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, and pharmaceutical payment assistance, as well as payroll.
  • Scale indicators for program reach: The company reports 6,500,000 cardholders and 573 plasma donation centers, with net 123 plasma centers added.

Bear case

  • Revenue is shown as 0.0B in the latest quarter data provided: The financials provided list revenue_b as 0.0 for 2026-03-31, which can signal small revenue, rounding, or volatility in the specific reporting view.
  • Segment mix clarity is limited in the provided data: Several candidate revenue labels for patient affordability are 0.0B, and the segment revenue candidates include overlapping naming, which makes it harder to confidently attribute performance across business lines.
  • Growth depends on expanding physical and program footprint: Key scale metrics relate to plasma donation centers and patient affordability programs, so execution and availability of new centers and programs can become a constraint.
Valuation — source: SEC EDGAR (first-party)
Price$14.09
Market Cap$795.55M
P/E Ratio40.1
EV / EBITDA19.7
Price / Book13.22
Price / Sales7.51
FCF Yield7.6%
DCF Value (model)$25.24
DCF Upside vs Price79.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$82.03M
Net Margin9.2%
Revenue Growth (YoY)40.5%
EPS Growth (YoY)100.0%
FCF Growth (YoY)127.6%
Financial Health — source: SEC EDGAR
Altman Z-Score2.61 (grey)
Piotroski F-Score6/9 (moderate)
Valuation vs Sector & Industry
Stock P/E40.1
Sector P/E (Technology)33.9
Industry P/E (Business Services)29.9
vs Sector18.4%
vs Industry34.2%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderTopline Capital Management, LLC ($27.37M)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryBusiness Services
CEOMark R. Newcomer
Employees173
CountryUS
IPO Date2007-10-10

Related Companies (Business model: IT Services / Consulting and Managed Services; 8 closest by market cap; US-domiciled)

  • Nutex Health, Inc. (NUTX)
  • QuinStreet, Inc. (QNST)
  • Emerald Holding, Inc. (EEX)
  • MediaAlpha, Inc. (MAX)
  • Phreesia, Inc. (PHR)
  • Cass Information Systems, Inc. (CASS)
  • Andersen (ANDG)
  • Claritev Corporation (CTEV)
PAYS earnings history · PAYS institutional & insider holders · PAYS KPIs & operating metrics · PAYS financials · PAYS investor presentations & press releases · PAYS SEC filings · PAYS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.